NHLBI funds new centers for cell-based therapy

September 29, 2005

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded the first three grants in a new research program on cell-based therapy of heart, lung, and blood diseases.

The program, Specialized Centers for Cell-Based Therapy for Heart, Lung, and Blood Diseases, involves both basic and clinical research but is heavily focused on clinical applications of cell-based therapy.

"Recent advances in stem cell biology and transplantation have set the stage for the next level of research emphasis: a program that emphasizes the translation of knowledge about cell-based therapy into clinical practice," said NHLBI Director Elizabeth G. Nabel, M.D.

According to Dr. Nabel, the $6.5 million program is anticipated to stimulate clinical research efforts on important public health problems for those with heart, lung, and blood diseases. The program will attempt to solve some of the problems and challenges of cell-based therapy including repair of damaged heart muscle, reducing immune complications due to graft versus host disease, and enhancing the interaction of adult stem cells and their tissue environment. Many of the 5-year studies will begin with preclinical animal or laboratory research to support an Investigational New Drug Application submission to the FDA followed by Phase I and II clinical studies for safety and effectiveness, respectively.

The centers awarded the grants and the principal investigators are:

  • Baylor College of Medicine, Houston, TX (Malcolm Brenner, M.D., Ph.D.) This group will focus on two clinical studies. In one study, the scientists will genetically modify donor immune cells used in stem cell therapy for treatment of patients with cancer and other diseases. The donor cells will be enhanced to speed recovery and reduce the effects of graft versus host disease, a potential complication of stem cell transplantation. The other clinical study involves modification of immune cells used in stem cell transplants to protect the recipients from the viral infections that are so common in immune compromised patients. A basic research study will investigate potential therapies using stem cells in the heart.

  • Johns Hopkins University, Baltimore, MD (Joshua Hare, M.D.) This research team will study the development of stem cell-based therapies to regenerate the heart and to reverse heart failure in patients with ischemic heart disease. The team will initially study the use of bone-marrow derived mesenchymal stem cells as a treatment for ischemia (reduced blood flow to the heart). Mesenchymal stem cells have the potential to develop into mature cells that produce fat, cartilage, bone, tendons, and muscle and have been shown to reduce heart damage in animals following a heart attack. In future years, the team will also study the use of human cardiac stem cells grown from small pieces of human heart tissue with the goal of delivering them back to patients following a heart attack.

  • Massachusetts General Hospital, Boston, MA (David Scadden, M.D.) This project team will focus on the specialized microenvironments where stem cells reside, targeting them to achieve stem cell therapies and tissue regeneration. Emphasis will be placed on the blood stem cell with laboratory and clinical studies using proteins to alter the stem cell microenvironment in the bone marrow. Treatment trials of stem cell therapies for individuals with hematologic cancers such as lymphoma, Hodgkin's disease and multiple myeloma will be the initial clinical studies performed.

  • The EMMES Corporation, Rockville, MD (Shelly Carter, Sc.D) EMMES will serve as the coordinating center for the program and will work with the Specialized Centers on establishing useful standard protocols for the emerging new field of cell-based therapies.
    -end-
    To interview an NHLBI spokesperson about this program, contact the NHLBI Communications Office at 301-496-4236. To interview Dr. Brenner, contact Ross Tomlin in the Office of Public Affairs at Baylor College of Medicine at (713) 798-7973; to interview Dr. Hare, contact David March at Johns Hopkins at 410-955-1534; to interview Dr. Scadden, contact Sue McGreevey at Massachusetts General Hospital Public Affairs at 617-724-2764; to contact Dr. Carter, call Sandi Sykes at 301-251-1161.

    NHLBI is part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NIH is a component of the U.S. Department of Health and Human Services. NHLBI press releases and publications, including background on cell-based therapies, can be found online at www.nhlbi.nih.gov.

    NIH/National Heart, Lung and Blood Institute

    Related Stem Cells Articles from Brightsurf:

    SUTD researchers create heart cells from stem cells using 3D printing
    SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

    More selective elimination of leukemia stem cells and blood stem cells
    Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

    Computer simulations visualize how DNA is recognized to convert cells into stem cells
    Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

    First events in stem cells becoming specialized cells needed for organ development
    Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

    Surprising research result: All immature cells can develop into stem cells
    New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

    The development of brain stem cells into new nerve cells and why this can lead to cancer
    Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

    Healthy blood stem cells have as many DNA mutations as leukemic cells
    Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

    New method grows brain cells from stem cells quickly and efficiently
    Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

    NUS researchers confine mature cells to turn them into stem cells
    Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

    Researchers develop a new method for turning skin cells into pluripotent stem cells
    Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

    Read More: Stem Cells News and Stem Cells Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.